Disease · MONDO_0004785
Comparisons in its trials12
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 12 of 12
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| ISV-305 vs Vehicle: deaths from any cause | 0 of 367 | 0 of 188 | 555 | NCT01543490 | Trial comparisons |
| ISV-305 vs Vehicle: serious adverse events | 4 of 367 | 0 of 188 | 555 | NCT01543490 | Trial comparisons |
| Active vs Control: deaths from any cause | 0 of 212 | 0 of 209 | 421 | NCT04475432 | Trial comparisons |
| Active vs Control: serious adverse events | 3 of 212 | 1 of 209 | 421 | NCT04475432 | Trial comparisons |
| Active vs Control: deaths from any cause | 0 of 203 | 0 of 209 | 412 | NCT04784091 | Trial comparisons |
| Active vs Control: serious adverse events | 4 of 203 | 3 of 209 | 412 | NCT04784091 | Trial comparisons |
| NCX 4251 vs Placebo: Treatment-emergent Adverse Events | 12 of 111 | 17 of 113 | 224 | NCT04675242 | Trial comparisons |
| NCX 4251 vs Placebo: deaths from any cause | 0 of 111 | 0 of 113 | 224 | NCT04675242 | Trial comparisons |
| NCX 4251 vs Placebo: serious adverse events | 0 of 111 | 0 of 113 | 224 | NCT04675242 | Trial comparisons |
| Doxycycline vs Oral Azithromycin: serious adverse events | 12 of 50 | 3 of 50 | 100 | NCT01783860 | Trial comparisons |
| Unifluid vs Azithromycin: serious adverse events | 0 of 43 | 0 of 50 | 93 | NCT01089608 | Trial comparisons |
| COL-101 (Doxycycline, USP) Capsules vs Placebo: serious adverse events | 1 of 46 | 1 of 24 | 70 | NCT00560703 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0004785/comparisons